In addition, our data show that treatment of T2DM stroke with CD133 + Exo significantly improves neurological function, cognitive function, white matter and vascular remodeling in the ischemic brain as well as reduces hepatic injury and progression of NAFLD/NASH compared to T2DM stroke mice. This evidence concerns the gene PROM1 and metabolic dysfunction-associated steatotic liver disease.